Vigil Neuroscience (NASDAQ:VIGL) Given “Market Outperform” Rating at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $23.00 target price on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $24.00 price target on shares of Vigil Neuroscience in a research note on Wednesday, March 27th.

Vigil Neuroscience Stock Performance

Shares of VIGL stock opened at $2.75 on Thursday. Vigil Neuroscience has a 1-year low of $2.53 and a 1-year high of $11.11. The stock’s fifty day moving average price is $3.17 and its 200 day moving average price is $4.02.

Vigil Neuroscience (NASDAQ:VIGL) last announced its earnings results on Tuesday, March 26th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.01). Sell-side analysts expect that Vigil Neuroscience will post -2.56 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several large investors have recently added to or reduced their stakes in VIGL. Vanguard Group Inc. grew its holdings in Vigil Neuroscience by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 799,197 shares of the company’s stock worth $2,701,000 after acquiring an additional 5,231 shares during the period. Barclays PLC grew its holdings in Vigil Neuroscience by 18.4% during the fourth quarter. Barclays PLC now owns 123,795 shares of the company’s stock worth $419,000 after acquiring an additional 19,205 shares during the period. Sphera Funds Management LTD. acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $1,809,000. Bridgeway Capital Management LLC acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $449,000. Finally, PEAK6 Investments LLC grew its holdings in Vigil Neuroscience by 74.3% during the fourth quarter. PEAK6 Investments LLC now owns 41,486 shares of the company’s stock worth $140,000 after acquiring an additional 17,690 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.